These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

569 related items for PubMed ID: 9734395

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Upregulation of the ligand-RAGE pathway via the angiotensin II type I receptor is essential in the pathogenesis of diabetic atherosclerosis.
    Ihara Y, Egashira K, Nakano K, Ohtani K, Kubo M, Koga J, Iwai M, Horiuchi M, Gang Z, Yamagishi S, Sunagawa K.
    J Mol Cell Cardiol; 2007 Oct; 43(4):455-64. PubMed ID: 17761193
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S.
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [Abstract] [Full Text] [Related]

  • 5. RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes.
    Wendt T, Harja E, Bucciarelli L, Qu W, Lu Y, Rong LL, Jenkins DG, Stein G, Schmidt AM, Yan SF.
    Atherosclerosis; 2006 Mar; 185(1):70-7. PubMed ID: 16076470
    [Abstract] [Full Text] [Related]

  • 6. The AGE/RAGE axis in diabetes-accelerated atherosclerosis.
    Jandeleit-Dahm K, Watson A, Soro-Paavonen A.
    Clin Exp Pharmacol Physiol; 2008 Mar; 35(3):329-34. PubMed ID: 18290873
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy.
    Yamagishi S, Takeuchi M, Inagaki Y, Nakamura K, Imaizumi T.
    Int J Clin Pharmacol Res; 2003 Mar; 23(4):129-34. PubMed ID: 15224502
    [Abstract] [Full Text] [Related]

  • 9. An update on advanced glycation endproducts and atherosclerosis.
    Del Turco S, Basta G.
    Biofactors; 2012 Mar; 38(4):266-74. PubMed ID: 22488968
    [Abstract] [Full Text] [Related]

  • 10. RAGE axis: Animal models and novel insights into the vascular complications of diabetes.
    Naka Y, Bucciarelli LG, Wendt T, Lee LK, Rong LL, Ramasamy R, Yan SF, Schmidt AM.
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1342-9. PubMed ID: 15155381
    [Abstract] [Full Text] [Related]

  • 11. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S, Ueda S, Okuda S.
    Med Hypotheses; 2007 Aug; 69(4):922-4. PubMed ID: 17368960
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S, Nakamura K, Inoue H.
    Med Hypotheses; 2005 Aug; 65(5):953-5. PubMed ID: 15996828
    [Abstract] [Full Text] [Related]

  • 15. Quantitative screening of advanced glycation endproducts in cellular and extracellular proteins by tandem mass spectrometry.
    Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, Dawnay A.
    Biochem J; 2003 Nov 01; 375(Pt 3):581-92. PubMed ID: 12885296
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products.
    Kaji Y, Usui T, Ishida S, Yamashiro K, Moore TC, Moore J, Yamamoto Y, Yamamoto H, Adamis AP.
    Invest Ophthalmol Vis Sci; 2007 Feb 01; 48(2):858-65. PubMed ID: 17251488
    [Abstract] [Full Text] [Related]

  • 17. Endogenous secretory receptor for advanced glycation end-products and cardiovascular disease in end-stage renal disease.
    Nishizawa Y, Koyama H.
    J Ren Nutr; 2008 Jan 01; 18(1):76-82. PubMed ID: 18089449
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Advanced glycation end-product of low density lipoprotein activates the toll-like 4 receptor pathway implications for diabetic atherosclerosis.
    Hodgkinson CP, Laxton RC, Patel K, Ye S.
    Arterioscler Thromb Vasc Biol; 2008 Dec 01; 28(12):2275-81. PubMed ID: 18818414
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.